Robert L. Cowie

TL;DR: Treatment with a macrolide, ethambutol, and clofazimine was successful in 20 of 30 patients with MAC lung disease and is a reasonable alternative to rifamycin-containing regimens.

TL;DR: It is hypothesize that individuals with unfavourable COPD “phenotypes” and subjects at-risk (ever smokers) with unhealthy lifestyle habits, environmental/work exposure, or co-morbidities will have increased risk of lung function decline independent of their cumulative exposure to cigarette smoke.

TL;DR: Chronic, uncomplicated silicosis was found to be associated with significant loss of lung function, and all of the measured indices, FVC, FEV1,FEV1/FVC%, maximal midexpiratory flow rate (MMEF), and lung diffusion for carbon monoxide measured by the single-breath method (DLCO) were reduced.

TL;DR: Clofazimine should be considered as an alternative drug for the treatment of MAC lung disease and both initial outcomes and re-treatment rates were at least as good in patients treated with clofazIMine-containing regimens as in patients receiving rifampin- containing regimens.

TL;DR: Although patients with undiagnosed COPD experience fewer exacerbations than those with diagnosed COPD, they use a similar amount of health services for exacerbation events; thus, the overall health system burden of exacerbations in those with Undiagnose COPD is considerable.